• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Activity of SM-4470, a new imidazole derivative, against experimental fungal infections.新型咪唑衍生物SM - 4470对实验性真菌感染的活性
Antimicrob Agents Chemother. 1986 Sep;30(3):366-9. doi: 10.1128/AAC.30.3.366.
2
Activity of UK-49,858, a bis-triazole derivative, against experimental infections with Candida albicans and Trichophyton mentagrophytes.双三唑衍生物UK-49,858对白色念珠菌和须癣毛癣菌实验性感染的活性。
Antimicrob Agents Chemother. 1985 May;27(5):832-5. doi: 10.1128/AAC.27.5.832.
3
In vivo efficacy of SM-8668 (Sch 39304), a new oral triazole antifungal agent.新型口服三唑类抗真菌药物SM-8668（Sch 39304）的体内疗效
Antimicrob Agents Chemother. 1990 Jun;34(6):980-4. doi: 10.1128/AAC.34.6.980.
4
Oxiconazole, a new imidazole derivative. Evaluation of antifungal activity in vitro and in vivo.奥昔康唑，一种新型咪唑衍生物。体外和体内抗真菌活性评估。
Arzneimittelforschung. 1982;32(1):17-24.
5
The antifungal activity of ketoconazole.酮康唑的抗真菌活性。
Am J Med. 1983 Jan 24;74(1B):9-15. doi: 10.1016/0002-9343(83)90508-9.
6
Antimycotic activity of BAY N 7133 in animal experiments.BAY N 7133在动物实验中的抗真菌活性。
J Antimicrob Chemother. 1984 May;13(5):447-63. doi: 10.1093/jac/13.5.447.
7
Preclinical antimycotic activity of SDZ 89-485: a new orally and topically effective triazole.SDZ 89 - 485的临床前抗真菌活性：一种新型口服和局部有效的三唑类药物。
J Med Vet Mycol. 1990;28(6):445-54. doi: 10.1080/02681219080000561.
8
Ketoconazole: a review of its therapeutic efficacy in superficial and systemic fungal infections.酮康唑：对其在浅表和全身性真菌感染中治疗效果的综述。
Drugs. 1982 Jan-Feb;23(1-2):1-36. doi: 10.2165/00003495-198223010-00001.
9
[Experiences with the oral antimycotic ketoconazole in vaginal fungal involvement].
Med Welt. 1982 Aug 20;33(33):1127-9.
10
Activity of terbinafine in experimental fungal infections of laboratory animals.特比萘芬在实验动物真菌感染中的活性。
Antimicrob Agents Chemother. 1987 Oct;31(10):1558-61. doi: 10.1128/AAC.31.10.1558.

引用本文的文献

1
In vivo efficacy of SM-8668 (Sch 39304), a new oral triazole antifungal agent.新型口服三唑类抗真菌药物SM-8668（Sch 39304）的体内疗效
Antimicrob Agents Chemother. 1990 Jun;34(6):980-4. doi: 10.1128/AAC.34.6.980.

本文引用的文献

1
In vivo antimycotic activity of naftifine.萘替芬的体内抗真菌活性。
Antimicrob Agents Chemother. 1981 Mar;19(3):390-2. doi: 10.1128/AAC.19.3.390.
2
Ketoconazole: a review of its therapeutic efficacy in superficial and systemic fungal infections.酮康唑：对其在浅表和全身性真菌感染中治疗效果的综述。
Drugs. 1982 Jan-Feb;23(1-2):1-36. doi: 10.2165/00003495-198223010-00001.
3
BAY b 5097, a new orally applicable antifungal substance with broad-spectrum activity.
Antimicrob Agents Chemother (Bethesda). 1969;9:271-4.
4
Nephrotoxicity of amphotericin B, with emphasis on changes in tubular function.
Am J Med. 1972 Jul;53(1):77-84.
5
Recent developments in antimycotic chemotherapy.
Infection. 1974;2(2):95-107. doi: 10.1007/BF01642028.
6
Activity of UK-49,858, a bis-triazole derivative, against experimental infections with Candida albicans and Trichophyton mentagrophytes.双三唑衍生物UK-49,858对白色念珠菌和须癣毛癣菌实验性感染的活性。
Antimicrob Agents Chemother. 1985 May;27(5):832-5. doi: 10.1128/AAC.27.5.832.
7
Antimicrobial activity of econazole and miconazole in vitro and in experimental candidiasis and aspergillosis.
Chemotherapy. 1976;22(3-4):211-20. doi: 10.1159/000221928.
8
Antifungal activity of tioconazole (UK-20,349), a new imidazole derivative.新型咪唑衍生物噻康唑（UK-20,349）的抗真菌活性
Antimicrob Agents Chemother. 1979 Apr;15(4):597-602. doi: 10.1128/AAC.15.4.597.
9
Ketoconazole -- a new broad spectrum orally active antimycotic.酮康唑——一种新型口服活性广谱抗真菌药。
Experientia. 1979 May 15;35(5):606-7. doi: 10.1007/BF01960348.

新型咪唑衍生物SM - 4470对实验性真菌感染的活性

Activity of SM-4470, a new imidazole derivative, against experimental fungal infections.

作者信息

Ichise K, Tanio T, Saji I, Okuda T

出版信息

Antimicrob Agents Chemother. 1986 Sep;30(3):366-9. doi: 10.1128/AAC.30.3.366.

DOI:10.1128/AAC.30.3.366
PMID:3777903
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC180561/
Abstract

The antifungal activity of orally active SM-4470, (R)-3-(n-butylthio)-2-(2,4-dichlorophenyl)-1-(imidazole-1-yl)-2-propanol hydrochloride, was compared with that of ketoconazole. SM-4470 showed twofold-higher activity than ketoconazole in the oral treatment of systemic infection with Candida albicans in mice. In addition, SM-4470 was effective against aspergillosis in mice, but ketoconazole was ineffective. The efficacy of SM-4470 was similar to that of ketoconazole in curing experimental candidal vaginitis in rats and trichophytosis in guinea pigs, although its serum concentrations in these animals were lower than those of ketoconazole. These data suggest that SM-4470 may be of value in the treatment of both systemic and superficial fungal infections in humans.

摘要

将口服活性药物SM-4470（(R)-3-(正丁硫基)-2-(2,4-二氯苯基)-1-(咪唑-1-基)-2-丙醇盐酸盐）的抗真菌活性与酮康唑进行了比较。在小鼠白色念珠菌全身性感染的口服治疗中，SM-4470的活性比酮康唑高两倍。此外，SM-4470对小鼠曲霉菌病有效，但酮康唑无效。在治愈大鼠实验性念珠菌性阴道炎和豚鼠皮肤癣菌病方面，SM-4470的疗效与酮康唑相似，尽管其在这些动物体内的血清浓度低于酮康唑。这些数据表明，SM-4470在治疗人类全身性和浅表性真菌感染方面可能具有价值。